Sinovac Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch SVA and buy or sell other stocks, ETFs, and their options commission-free!

About SVA

Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. 

CEO
Wei Dong Yin
CEOWei Dong Yin
Employees
3,037
Employees3,037
Headquarters
Beijing, Beijing
HeadquartersBeijing, Beijing
Founded
1993
Founded1993
Employees
3,037
Employees3,037

SVA Key Statistics

Market cap
464.94M
Market cap464.94M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
Average volume
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$6.47
52 Week high$6.47
52 Week low
$6.47
52 Week low$6.47

Stock Snapshot

The current Sinovac Biotech(SVA) stock price is $6.47, with a market capitalization of 464.94M.

On 2026-02-08, Sinovac Biotech(SVA) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for Sinovac Biotech(SVA) stock has reached 0.

The stock's 52-week range extends from a low of $6.47 to a high of $6.47.

The stock's 52-week range extends from a low of $6.47 to a high of $6.47.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.